Price movement over the last 24 hours
Alcon AG vs Wells Fargo & Co — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Wells Fargo & Co trades at $85.71 (market cap $266.79B). The key difference: Wells Fargo & Co is far larger — about 8.2× Alcon AG's market cap, and Wells Fargo & Co pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| ALC | WFC | |
|---|---|---|
Market Cap | $32.69B | $266.79B |
Sector | Health | Financials |
52-Week High | $92.22 | $96.40 |
52-Week Low | $62.02 | $73.42 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 2.06% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Wells Fargo (WFC) trades at $87.21, up 1.99% on the day, with a bullish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.52, net income margin of 25.53%, and ROE of 12.7%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company announced a dividend of $0.45 payable in June 2026, and Q2 2026 earnings are expected on July 14, 2026, with an EPS estimate of 1.73.
The outlook for WFC is cautiously optimistic, supported by analyst consensus with a $98.25 price target and 45% buy ratings. Key opportunities include potential earnings growth and dividend increases post-Fed stress tests. Risks involve volatile cash flows, regulatory changes impacting debit card fees, and competitive pressures in the banking sector. The stock's valuation remains attractive, but investors should monitor upcoming earnings for confirmation of growth trends.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →